Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways.

ABSTRACT

Elevated levels of epidermal growth factor receptor (EGFR) have been detected in a variety of human cancers. Several reports have demonstrated that the Type III EGF receptor deletion-mutant (EGFRvIII) is frequently detected in various human cancers, including breast cancer. We generated and characterized monoclonal antibody against EGFRvIII. We demonstrated that 29% of DCIS, 40% of primary invasive breast cancers and 54% of metastatic lymph nodes express EGFRvIII by immunohistochemical analysis with two monoclonal antibodies. High levels of EGFRvIII expression were detected in about 5% of primary breast cancer and 27% of metastatic lymph-nodes. Furthermore, in the positive samples, the normal mammary gland exhibited negative staining for EGFRvIII, while the tumor cells were positive. The frequency of EGFRvIII expression correlated with breast cancer progression. We also showed that, despite the absence of gene amplification of EGFR in breast carcinoma cells, EGFRvIII was phosphorylated in breast cancer. In addition, approximately 40% of ErbB-2 positive primary breast tumors were found to co-express EGFRvIII. Even more striking is that 75% (3/4) of ErbB-2 positive metastatic lymph node specimens co-expressed with EGFRvIII. Co-expression of EGFRvIII with ErbB-2 in 32D cells amplified downstream signaling cascades and significantly enhanced tumorigenesis in vivo. Furthermore, EGFRvIII mediated constitutively activated and sustained downstream signaling pathways, whereas EGF-ligand induced a transient effect on wt-EGFR-mediated downstream signaling pathways.